 LEXINGTON, Mass., May 19, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC, a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. 